Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GNGBY declined for three days, in of 242 cases, the price declined further within the following month. The odds of a continued downward trend are .
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for GNGBY turned negative on February 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
GNGBY broke above its upper Bollinger Band on February 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on GNGBY as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNGBY advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 275 cases where GNGBY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.729) is normal, around the industry mean (23.448). P/E Ratio (24.876) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (23.058) is also within normal values, averaging (5.667). Dividend Yield (0.022) settles around the average of (0.018) among similar stocks. P/S Ratio (1.802) is also within normal values, averaging (41.230).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GNGBY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNGBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
Industry MedicalSpecialties
A.I.dvisor tells us that GNGBY and CNMD have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNGBY and CNMD's prices will move in lockstep.
Ticker / NAME | Correlation To GNGBY | 1D Price Change % | ||
---|---|---|---|---|
GNGBY | 100% | +3.47% | ||
CNMD - GNGBY | 32% Poorly correlated | -2.71% | ||
ALGN - GNGBY | 29% Poorly correlated | -1.85% | ||
AVNS - GNGBY | 28% Poorly correlated | -0.83% | ||
SNN - GNGBY | 27% Poorly correlated | +0.39% | ||
AEMD - GNGBY | 26% Poorly correlated | -2.51% | ||
More |